Compare · IVVD vs REGN

IVVD vs REGN

Side-by-side comparison of Invivyd Inc. (IVVD) and Regeneron Pharmaceuticals Inc. (REGN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. IVVD focuses on Biotechnology: Biological Products (No Diagnostic Substances), while REGN focuses on Biotechnology: Pharmaceutical Preparations.
  • REGN is the larger of the two at $98.52B, about 616.8x IVVD ($159.7M).
  • Over the past year, IVVD is down 81.1% and REGN is up 35.3% - REGN leads by 116.4 points.
  • REGN has been more active in the news (18 items in the past 4 weeks vs 4 for IVVD).
  • REGN has more recent analyst coverage (25 ratings vs 7 for IVVD).
PerformanceIVVD-81.08%REGN+35.34%
2025-11-17+0.00%2026-11-16
MetricIVVDREGN
Company
Invivyd Inc.
Regeneron Pharmaceuticals Inc.
Price
-
-
Market cap
$159.7M
$98.52B
1M return
-13.22%
+20.40%
1Y return
-81.08%
+35.34%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2021
1991
News (4w)
4
18
Recent ratings
7
25
REGN

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Latest IVVD

Latest REGN